Oprozomib [ONX 0912]

CHF 60.00
In stock
AG-CR1-3672-M0011 mgCHF 60.00
AG-CR1-3672-M0055 mgCHF 145.00
AG-CR1-3672-M02525 mgCHF 435.00
More Information
Product Details
Synonyms O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-L-serinamide; PR-047
Product Type Chemical
Properties
Formula

C25H32N4O7S

MW 532.6
CAS 935888-69-0
Purity Chemicals ≥98% (HPLC)
Appearance White solid.
Solubility Soluble in DMSO (20mg/ml) or DMF (10mg/ml). Sparingly soluble in ethanol (1mg/ml). Poorly soluble in aqueous buffers.
Identity Determined by 1H-NMR.
Other Product Data

Note: Warming and sonication may be required when dissolving the compound in the solvent of choice. Stock solutions are stable for at least 1 month when stored at -20°C.

InChi Key SWZXEVABPLUDIO-WSZYKNRRSA-N
Smiles O=C([C@]1(CO1)C)[C@H](CC2=CC=CC=C2)NC([C@H](COC)NC([C@H](COC)NC(C3=CN=C(C)S3)=O)=O)=O
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Keep cool and dry.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF
  • Potent orally bioavailable irreversible proteasome inhibitor. Analog of Carfilzomib (Prod. No. AG-CR1-3669).
  • Targets the chymotrypsin-like β5 subunit of the constitutive 20S proteasome (IC50=36nM) and the β5i subunit [LMP7] of the 20S immunoproteasome (IC50=82nM).
  • Anticancer compound effective in cell-based assays, in xenografts and against multiple myeloma in vivo.
  • In vitro, induces cell cycle arrest and apoptosis in human cancer cell lines including multiple myeloma, as well as in bortezomib resistant multiple myeloma cells.
  • Shown to have anti-angiogenic activity.
  • Has potential applications in certain types of cancer as well as other diseases that require proteasome activity.
Product References
  1. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047): H.J. Zhou, et al.; J. Med. Chem. 52, 3028 (2009)
  2. A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma: D. Chauhan, et al.; Blood 116, 4906 (2010)
  3. The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects: M.A. Hurchla, et al.; Leukemia 27, 430 (2013)
  4. Carfilzomib and ONX 0912 inhibit cell survival and tumor growth of head and neck cancer and their activities are enhanced by suppression of Mcl-1 or autophagy: Y. Zang, et al.; Clin. Cancer Res. 18, 5639 (2012)
  5. The next generation proteasome inhibitors carfilzomib and oprozomib activate prosurvival autophagy via induction of the unfolded protein response and ATF4: Y. Zang, et al.; Autophagy 8, 1873 (2012)
  6. Effect of novel proteasome and immunoproteasome inhibitors on dendritic cell maturation, function, and expression of IκB and NFκB: A.S. Al-Homsi, et al.; Transpl. Immunol. 29, 1 (2013)
  7. Overview of proteasome inhibitor-based anti-cancer therapies: Perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system: Q.P. Dou & J.A. Zonder; Curr. Cancer Drug Targets 14, 517 (2014)
  8. Proteasome inhibitors - molecular basis and current perspectives in multiple myeloma: L. Kubiczkova, et al.; J. Cell. Mol. Med. 18, 947 (2014)
  9. Next-generation proteasome inhibitor oprozomib synergizes with modulators of the unfolded protein response to suppress hepatocellular carcinoma: Y.P. Vandewynckel, et al.; Oncotarget 7, 34988 (2016)
  10. Second Generation Proteasome Inhibitors in Multiple Myeloma: A. Gozzetti, et al.; Anticancer Agents Med. Chem. 17, 920 (2017)
  11. Anti-angiogenic and anti-multiple myeloma effects of oprozomib (OPZ) alone and in combination with pomalidomide (Pom) and/or dexamethasone (Dex): E. Sanchez, et al.; Leuk. Res. 57, 45 (2017) (Review)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.